MK-3475
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
9543Background: cSCC is the second most common skin cancer in the U.S. with over 700,000 new cases and 2000 deaths per year…
TPS1102Background: Pembrolizumab is a humanized monoclonal antibody against PD-1 that blocks the PD-1–ligand interaction…
TPS183 Background: Pembrolizumab (pembro) is a humanized monoclonal antibody against PD-1 that prevents PD-1 from interacting…
TPS5612Background: Recurrent epithelial ovarian, fallopian, and peritoneal cancer (EOC) is the leading cause of gynecologic…
TPS4571 Background: Paclitaxel, docetaxel, and vinflunine are commonly used as second-line therapy for advanced urothelial cancer…
The overall objective of the fifth American Association for Cancer Research Special Conference, “Tumor Immunology and…
Background: Currently approved cytotoxic chemotherapies for patients with previously treated NSCLC produce few objective…
TPS4604^ Background: Pazopanib is an angiogenesis inhibitor targeting VEGFR-1, -2, and -3; PDGFR-α and -β; and the receptor c-Kit…
9009Background: Programmed death-1 (PD-1) is an inhibitory T-cell co-receptor that may lead to suppression of antitumor immunity…
Programmed death 1 (PD-1) is a T cell co-inhibitory receptor with two ligands, PD-L1 and PD-L2. In cancer, this pathway plays a…